JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

Julie R. Brahmer,Melissa L. Johnson,Manuel Cobo,Santiago Viteri, Juan Coves Sarto,Ammar Sukari,Mark M. Awad,Ravi Salgia,Vali A. Papadimitrakopoulou,Arun Rajan,Nibedita Bandyopadhyay,Alicia J. Allred,Mark Wade,Gary E. Mason,Enrique Zudaire,Roland E. Knoblauch,Nicole Stone,Matthew V. Lorenzi,Raffit Hassan

JTO Clinical and Research Reports（2021）

引用 9|浏览23

暂无评分

摘要

As monotherapy, JNJ-757 was immunogenic and tolerable, with mild infusion-related fever and chills. The limited efficacy of JNJ-757, alone or with nivolumab, did not warrant further investigation of the combination.

查看译文

关键词

Non–small cell lung cancer,Mesothelin,LADD Lm,JNJ-757,Vaccine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要